CAR-T & Cellular Therapy
iwNHL 2021: immunotherapy and the microenvironment
Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma….
Date: 23rd July 2021
The Myeloma Sessions: key highlights from EHA and ASCO 2021
The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…
Date: 21st July 2021
The AML Sessions: Highlights from ASCO/EHA 2021
Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…
Date: 7th July 2021
Key updates on CAR-T therapy for ALL
There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (around 75% of cases)….
Date: 5th July 2021
Latest updates on CAR-T therapy for CLL
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory…
Date: 16th June 2021
The Myeloma Sessions: post-COMy 2021 roundtable
Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared…
Date: 3rd June 2021
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults…
Date: 28th May 2021
Key updates on CAR-T & cellular therapy for AML
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically…
Date: 17th May 2021
The Transplant Sessions: ASH 2020 highlights
The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…
Date: 23rd April 2021
The Lymphoma Sessions: ASH 2020 highlights
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific…
Date: 23rd April 2021
The Post-EBMT VJSessions from VJHemOnc
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…
Date: 7th April 2021
The CLL Sessions: highlights from ASH 2020
Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America….
Date: 17th March 2021
